Lisata Therapeutics (LSTA) AI Stock Analysis

• Market Cap: $40.22M
• Dividend Yield: N/A
• Average Volume (3M): 34.52K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.67
• Revenue Growth: N/A
• EPS Growth: 15.32%
• Country: US
• Employees: 26
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.49
• Shares Outstanding: 8,820,733
• 10 Day Avg. Volume: 57,561
• 30 Day Avg. Volume: 34,515
• PEG Ratio: 0.18
• Price to Book (P/B): 0.84
• Price to Sales (P/S): 24.82
• P/FCF Ratio: -1.28
• Enterprise Value/Market Cap: 0.53
• Enterprise Value/Revenue: 20.00
• Enterprise Value/Gross Profit: 20.00
• Enterprise Value/Ebitda: -1.10
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Hold
• Number of Analyst Covering: 1
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 52 Neutral
• Price Target: $4.00 ▲(105.13% Upside)

The score is held back primarily by weak financial performance (minimal revenue, large losses, and significant cash burn). Offsetting factors include strong recent technical trend (though overbought), constructive earnings-call progress on expense reductions and runway, and mixed but impactful corporate developments (buyout offer positive, China deal termination negative).

Positive Factors

Debt-free balance sheet

Zero reported debt materially reduces fixed financing costs and bankruptcy risk, giving management flexibility to prioritize R&D, licensing or selective M&A. Over multiple quarters this lowers cash outflows for interest, supporting longer runway vs. indebted peers while clinical programs mature.

Strategic partnerships & licensing

A global license with Catalent and alliances like GATC Health create durable commercialization and development pathways without Lisata funding all downstream trials. Such partnerships validate the platform, broaden addressable markets, and enable non-dilutive milestones/licensing revenues over the medium term.

Clinical proof-of-concept signals

Repeated positive trial signals (ASCEND preliminary trends and investigator-initiated CENDIFOX results) strengthen the biological rationale and de-risk development. Durable efficacy/safety evidence enhances partner interest, supports regulatory planning and increases chance of successful registration or strategic exits over 2–6 months.

Negative Factors

Low revenue & large losses

Revenue scale is insufficient to support operating cost base, producing structurally negative margins and persistent operating losses. Without material revenue diversification or margin improvement, the company cannot self-fund registrational studies and remains dependent on external financing or partnerships.

Material cash burn

Sustained negative OCF and FCF mean the company will need additional capital before commercialization. This constrains ability to initiate large Phase III programs, raises dilution or partnership dependency risk, and forces prioritization of programs which can slow broader pipeline progress.

Loss of China collaboration

Termination of the Qilu Greater China license removes a potentially large non-dilutive funding and regional commercialization path. Recovering those economics will require new licensing, re-negotiation or local buildout, delaying market access and increasing near-term funding pressure and execution complexity.

Lisata Therapeutics Business Overview & Revenue Model

Company Description

Lisata Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing cellular therapies to reverse disease and/or promote the regeneration of damaged tissue. Its product candidates include HONEDRA, a recipient of SAKIGAKE designation that is in Phase II clinical trial for the treatment of critical limb ischemia; XOWNA that is in Phase IIb clinical trial for the treatment of coronary microvascular dysfunction; and CLBS201, a CD34+ cell therapy for the treatment of pre-dialysis patients with chronic kidney disease. The company was formerly known as NeoStem, Inc. and changed its name to Caladrius Biosciences, Inc. in June 2015. The company was formerly known as Caladrius Biosciences, Inc. and changed its name to Lisata Therapeutics, Inc. on September 15, 2022. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

How the Company Makes Money

Lisata Therapeutics generates revenue primarily through the development and commercialization of its drug candidates. The company may earn money via partnerships with larger pharmaceutical companies, licensing agreements, and potential sales of its approved therapies. Additionally, Lisata could receive milestone payments and royalties based on the successful development and commercialization of its products. However, as a clinical-stage company, Lisata's revenue generation is typically dependent on the progression of its drug candidates through clinical trials and eventual regulatory approvals.

Lisata Therapeutics Financial Statement Overview

Summary

Financials remain weak overall: revenue is very small (~$1.07M TTM) with large operating losses (EBIT about -$20.1M) and deeply negative margins. The balance sheet benefits from zero debt, but equity/assets have declined and ROE is strongly negative (~-78%). Cash burn is material (operating cash flow about -$17.2M; FCF about -$17.3M), implying continued reliance on funding despite some improvement versus 2024.

Income Statement

TTM (Trailing-Twelve-Months) revenue remains very small (~$1.07M) with no growth, which limits operating leverage. While gross profit is high (near full revenue), operating costs are far above the revenue base, driving large operating losses (EBIT of about -$20.1M) and a deeply negative net margin. Losses have improved versus 2022, but profitability is still structurally weak given the current revenue scale.

Balance Sheet

Leverage is a clear strength: TTM (Trailing-Twelve-Months) total debt is $0 and historically debt-to-equity has been very low, reducing balance-sheet risk. However, equity and total assets have declined materially over time (from 2021–2022 levels to TTM), reflecting ongoing losses and balance-sheet burn. Returns to shareholders are strongly negative (TTM return on equity around -78%), highlighting that the capital base is not currently generating profits.

Cash Flow

Cash generation is a key weakness: TTM (Trailing-Twelve-Months) operating cash flow is about -$17.2M and free cash flow is about -$17.3M, indicating continued cash burn to fund operations. Cash burn has improved versus 2024 (less negative), but the business still relies on external funding until revenues scale or expenses reset meaningfully. Free cash flow roughly tracks net losses, suggesting limited non-cash offsets.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	1.07M	1.00M	0.00	0.00	0.00	0.00
Gross Profit	1.07M	1.00M	0.00	0.00	0.00	-63.00K
EBITDA	-19.53M	-22.23M	-25.52M	-57.53M	-29.00M	-19.08M
Net Income	-18.24M	-19.98M	-20.84M	-54.23M	-27.47M	-8.15M
Balance Sheet
Total Assets	21.76M	35.00M	54.69M	73.03M	97.01M	36.00M
Cash, Cash Equivalents and Short-Term Investments	19.00M	31.25M	50.53M	69.23M	94.97M	34.57M
Total Debt	0.00	137.00K	168.00K	485.00K	714.00K	624.00K
Total Liabilities	4.64M	5.68M	6.80M	6.71M	5.01M	3.76M
Stockholders Equity	17.37M	29.57M	48.15M	66.58M	92.25M	32.50M
Cash Flow
Free Cash Flow	-17.28M	-19.36M	-20.03M	-21.45M	-22.30M	-8.84M
Operating Cash Flow	-17.23M	-19.36M	-20.03M	-21.17M	-22.25M	-8.82M
Investing Cash Flow	16.48M	13.23M	10.10M	28.91M	-54.90M	-7.28M
Financing Cash Flow	298.00K	-206.00K	385.00K	-224.00K	85.28M	18.58M

Lisata Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 1.95
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For LSTA, the sentiment is Positive. The current price of 1.95 is below the 20-day moving average (MA) of 3.24, below the 50-day MA of 2.49, and below the 200-day MA of 2.48, indicating a bullish trend. The MACD of 0.69 indicates Negative momentum. The RSI at 86.67 is Negative, neither overbought nor oversold. The STOCH value of 72.92 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for LSTA.

Lisata Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
LSTA	52 Neutral	$40.22M	-2.15	-71.45%	―	―	15.32%
APLM	52 Neutral	$24.02M	-0.69	-380.13%	―	―	54.41%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
CTXR	48 Neutral	$15.77M	-0.21	-54.40%	―	―	18.73%
APVO	43 Neutral	$7.52M	>-0.01	-256.30%	―	―	99.02%
PCSA	41 Neutral	$5.95M	-0.07	-270.74%	―	―	72.88%

Lisata Therapeutics Corporate Events

Lisata Therapeutics ends Qilu certepetide collaboration deal

On January 23, 2026, Lisata Therapeutics, Inc. and Qilu Pharmaceutical Co., Ltd. mutually agreed to terminate their exclusive license and collaboration agreement, originally signed in February 2021 and subsequently amended, which had granted Qilu rights to research, develop and commercialize certepetide in Greater China. The termination, effective the same day, eliminates Lisata’s potential to receive up to $200 million in development and commercial milestone payments and 10%–15% royalties on sales in that territory, although both parties remain bound by obligations and certain provisions that accrued or were designated to survive prior to the termination, signaling a strategic shift in Lisata’s regional commercialization plans for certepetide.

The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Lisata Therapeutics Agrees to All-Cash Acquisition by Kuva

On January 20–21, 2026, Lisata Therapeutics announced it had entered into a binding term sheet with privately held Kuva Labs for a negotiated acquisition via an all‑cash tender offer of $4.00 per share, to be followed by a short‑form merger, with Lisata stockholders also eligible for two non‑tradeable contingent value rights worth up to an additional $2.00 per share upon achieving specified certepetide‑related milestones. The offer, unanimously approved by both companies’ boards and expected to be formalized in a definitive purchase agreement before February 27, 2026, represents roughly an 85% premium to Lisata’s most recent closing price, or about 180% including the CVRs, and is structured with exclusivity, standstill and break‑up fee provisions that protect both parties while allowing Lisata to consider superior competing bids; the deal underscores the strategic value Kuva sees in Lisata’s certepetide‑based oncology platform and could deliver a substantial liquidity event for shareholders if the tender offer and subsequent merger close as planned.

The most recent analyst rating on (LSTA) stock is a Hold with a $2.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.

Lisata Therapeutics Reports Q3 Results and Strategic Alliances

On November 6, 2025, Lisata Therapeutics reported its third-quarter financial results, highlighting positive data from clinical studies involving certepetide, a promising investigational drug for solid tumors. The company announced strategic alliances and a global license agreement, extending its cash runway into early 2027, and anticipates further data releases to bolster its market position.

The most recent analyst rating on (LSTA) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Lisata Therapeutics stock, see the LSTA Stock Forecast page.